InBio, LLC   Report issue

For profit Phase 2
Founded: Tallinn Estonia (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2019
NCT04099381
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

INBIO, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

cord blood hematopoietic stem cell (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Cerebral Palsy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1